In Scotland, a newly licensed medicine is routinely available in a health board only after it has been:

- accepted for use in NHS Scotland by the Scottish Medicines Consortium (SMC), and
- accepted for use by the health board's Area Drug and Therapeutics Committee (ADTC).

All medicines accepted by SMC are available in Scotland, but may not be considered 'routinely available' within a particular health board because of available services and preferences for alternative medicines.

'Routinely available' means that a medicine can be prescribed by the appropriately qualified person within a health board.

Each health board has an ADTC. The ADTC, Grampian Area Drug and Therapeutics Committee, is responsible for advising NHS Grampian health board on all aspects of the use of medicines.

Medicines routinely available within NHS Grampian are usually included in the Grampian Joint Formulary. The formulary is a list of medicines for use in the health board that has been agreed by the ADTC in consultation with local clinical experts. It offers a choice of medicines for healthcare professionals to prescribe for common medical conditions. A formulary can help improve safety as prescribers are likely to become more familiar with the medicines in it and also helps make sure that standards of care are consistent across the health board.

How does the health board decide which new medicines to make routinely available for patients?

The ADTC in a health board will consider national and local guidance before deciding whether to make a new medicine routinely available.

What national guidance does the ADTC consider?

- SMC advice: The SMC considers newly licensed medicines and advises health boards in Scotland whether they should be available. When SMC considers a new medicine for the NHS in Scotland, it looks at:
  - how well the medicine works,
  - which patients might benefit from it,
  - whether it is as good or better than medicines the NHS already uses to treat the medical condition, and
  - whether it is good value for money.
- In the table below, national guidance usually refers to SMC advice. Links to SMC advice for individual medicines are also included in the table.
- In some cases, other agencies may also provide guidance on how medicines should be used. For example, Healthcare Improvement Scotland issues alerts to advise if National Institute for Health and Care Excellence Multiple Technology Appraisals (NICE MTAs) are applicable in Scotland.

What local guidance does the ADTC consider?

- Advice from local clinical experts who would be expected to prescribe a particular medicine, where that service is available in a health board.

Why is a particular medicine not routinely available in NHS Grampian?

- This is usually because the medicine is not recommended for use in NHS Scotland by the SMC.
- The medicine may not be routinely available in a health board, particularly in smaller health boards, because there is not a suitable specialist who may use the medicine.
- There may also be differences as to which medicines are preferred in health boards. Sometimes SMC accepts more than one medicine for treating a specific medical condition. Clinical experts in each health board consider whether to add new medicines to their formulary and advise the ADTC. Sometimes it is agreed that established medicines are a better choice than new medicines.

What happens if a particular medicine is not routinely available in NHS Grampian?

- If a medicine is not routinely available and not included in the Grampian Joint Formulary and there are no suitable alternatives on the formulary, a healthcare professional can request to prescribe a medicine that is not on the formulary if they think you will benefit from using it. All health boards have procedures in place to consider requests when a healthcare professional feels a medicine that is not on the formulary would be right for a particular patient.

The table below lists NHS Grampian's latest decisions on medicines.

If you need more information on medicines decisions in NHS Grampian, please email gram.formularyteam@nhs.scot.




Image courtesy of Baitong333 - image ID: 100128772/ FreeDigitalPhotos.net

This document is also available in large print and other formats and languages, upon request. Please call NHS Grampian Corporate Communications on (01224) 551116 or (01224) 552245.

Name	Unique identifier	Condition being treated	NHS Grampian decision	Date of decision
acalabrutinib 100mg film-coated tablets (Calquence®)	2985	As monotherapy for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) not previously treated with a BTK inhibitor.	Not routinely available as not recommended for use in NHS Scotland, SMC 2985 https://scottishmedicines.org.uk/media/10697/acalabrutinib-calquence-non-sub-final-sept-2026-for-website.pdf	20/10/2026
acoramidis 356mg film-coated tablets (Beyonttra®)	2986	Treatment of wild-type or variant transthyretin amyloidosis in adult patients with cardiomyopathy (ATTR-CM).	Not routinely available as not recommended for use in NHS Scotland, SMC 2986 https://scottishmedicines.org.uk/media/10698/acoramidis-beyonttra-non-sub-final-sept-2026-for-website.pdf	20/10/2026
atogepant 10mg, 60mg tablets (Aquipta®)	2934	Acute treatment of migraine with or without aura in adults. **SMC restriction:** patients who have had inadequate symptom relief after trials of at least two triptans, or in whom triptans are contraindicated or not tolerated; and have inadequate pain relief with non-steroidal anti-inflammatory drugs (NSAIDs) and paracetamol.	Not routinely available as the ADTC is waiting for further advice from local clinical experts	20/10/2026
ciclosporin 25mg, 50mg, 100mg capsules (Capimune®)		- Solid organ transplantation - Bone marrow transplantation - Endogenous uveitis - Nephrotic syndrome - Rheumatoid arthritis - Psoriasis - Atopic dermatitis	This medicine is now withdrawn from use/discontinued	20/10/2026
deuruxolitinib 8mg film-coated tablets (Leqselvi®)	2968	Treatment of adult patients with severe alopecia areata.	Not routinely available as the ADTC is waiting for further advice from local clinical experts	20/10/2026

Name	Unique identifier	Condition being treated	NHS Grampian decision	Date of decision
disopyramide 100mg capsules (Rythmodan®)		For the treatment of cardiac arrhythmias as follows: 1. The prevention and treatment of arrhythmias occurring after myocardial infarction. 2. Maintenance of normal rhythm following electroconversion e.g. atrial fibrillation, atrial flutter. 3. Persistent ventricular extrasystoles. 4. Control of arrhythmias following the use of digitalis or similar glycosides. 5. Suppression of arrhythmias during surgical procedures e.g. cardiac catheterisation. 6. The prevention of paroxysmal supraventricular tachycardia. 7. Other types of arrhythmias e.g. atrial extrasystoles, Wolff-Parkinson-White Syndrome.	This medicine is now withdrawn from use/discontinued	20/10/2026
disopyramide 250mg modified-release tablets (Rythmodan® Retard)		Prevention and control of a wide variety of cardiac arrhythmias, probably by slowing conduction in the his-Purkinje system and by increasing the effective refractory period of the atria and ventricles. Indications: 1. Maintenance of normal rhythm following conversion by parenteral drugs or electroconversion. 2. Prevention of arrhythmias after myocardial infarction. 3. Treatment of persistent ventricular and atrial extrasystoles, paroxysmal supra ventricular tachycardia, Wolff-Parkinson-White syndrome. 4. Suppression of arrhythmias during surgical procedures. 5. Control of arrhythmias following the use of digitalis or similar glycosides.	This medicine is now withdrawn from use/discontinued	20/10/2026

Name	Unique identifier	Condition being treated	NHS Grampian decision	Date of decision
glofitamab 1mg/mL concentrate for solution for infusion (Columvi®)	2846	In combination with gemcitabine and oxaliplatin for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma not otherwise specified (DLBCL NOS) who are ineligible for autologous stem cell transplant (ASCT) and who have progressed during or after one systemic therapy only (i.e., in the second-line setting).	Routinely available in line with national guidance, SMC 2846 https://scottishmedicines.org.uk/media/10461/glofitamab-columvi-final-june-2026-for-website.pdf	20/10/2026
inavolisib 3mg, 9mg film-coated tablets (Itovebi®)	2902	In combination with palbociclib and fulvestrant, for the treatment of adult patients with PIK3CA-mutated, oestrogen receptor (ER) positive, HER2 negative, locally advanced or metastatic breast cancer, following recurrence on or within 12 months of completing adjuvant endocrine treatment.	Not routinely available as not recommended for use in NHS Scotland, SMC 2902 https://scottishmedicines.org.uk/media/10709/inavolisib-itovebi-final-sept-2026-amended-091026-for-website.pdf	20/10/2026
mirvetuximab soravtansine 5mg/mL concentrate for solution for infusion (Elahere®)	2892	As monotherapy for the treatment of adult patients with folate receptor-alpha (FRα) positive, platinum-resistant high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior systemic treatment regimens.	Not routinely available as the ADTC is waiting for further advice from local clinical experts	20/10/2026
nusinersen 50mg, 28mg solution for injection (Spinraza®)	2959	For the treatment of 5q Spinal Muscular Atrophy (SMA). **SMC restriction:** patients with pre-symptomatic and symptomatic type 1 (infantile-onset) and type 2 or type 3 (later-onset) 5q SMA.	Not routinely available as the ADTC is waiting for further advice from local clinical experts	20/10/2026
obinutuzumab 1,000mg concentrate for solution for infusion (Gazyvaro®)	2903	In combination with mycophenolate mofetil (MMF), for the treatment of adult patients with active Class III or IV, with or without concomitant Class V, lupus nephritis (LN).	Not routinely available as the ADTC is waiting for further advice from local clinical experts	20/10/2026

Name	Unique identifier	Condition being treated	NHS Grampian decision	Date of decision
palopegteriparatide 168micrograms/0.56mL, 294micrograms/0.98mL, 420micrograms/1.4mL solution for injection in pre-filled pen (Yorvipath®)	2887	The treatment of adults with chronic hypoparathyroidism.	Not routinely available as not recommended for use in NHS Scotland, SMC 2887 https://scottishmedicines.org.uk/media/10706/palopegteriparatide-yorvipath-final-sept-2026-for-website.pdf	20/10/2026
pomalidomide 1mg, 2mg, 3mg, 4mg hard capsules	119	[Off-label use] in combination with dexamethasone for the treatment of adults with multiple myeloma who have received one prior treatment regimen including lenalidomide, and where more effective alternatives are not suitable.	Routinely available in line with national guidance, NCMAG 119 https://www.healthcareimprovementscotland.scot/wp-content/uploads/2025/02/NCMAG119-Pom-Dex-Advice-Document-v1.0.pdf	20/10/2026
pomalidomide 1mg, 2mg, 3mg, 4mg hard capsules	120	In combination with bortezomib plus dexamethasone for the treatment of adults with multiple myeloma who have received at least one prior treatment regimen including lenalidomide.	Routinely available in line with national guidance, NCMAG 120 https://www.healthcareimprovementscotland.scot/wp-content/uploads/2025/02/NCMAG120-Pom-Dex-Bort-Advice-Document-v1.0.pdf	20/10/2026
risdiplam 5mg film-coated tablets (Evrysdi®)		For the treatment of 5q spinal muscular atrophy (SMA) in patients with a clinical diagnosis of SMA Type 1, Type 2 or Type 3 or with one to four SMN2 [survival of motor neuron 2] copies.	Routinely available in line with local guidance	20/10/2026
selumetinib 10mg, 25mg hard capsules (Koselugo®)	2987	As monotherapy for the treatment of symptomatic, inoperable plexiform neurofibromas (PN) in adult patients with neurofibromatosis type 1 (NF1).	Not routinely available as not recommended for use in NHS Scotland, SMC 2987 https://scottishmedicines.org.uk/media/10694/selumetinib-koselugo-non-sub-final-sept-2026-for-website.pdf	20/10/2026

Name	Unique identifier	Condition being treated	NHS Grampian decision	Date of decision
semaglutide 1.5mg, 4mg, 9mg, 25mg tablets (Wegovy®)	2988	As an adjunct to a reduced-calorie diet and increased physical activity for weight management, including weight loss and weight maintenance, in adults with an initial Body Mass Index (BMI) of: - ≥30 kg/m2 (obesity), or - ≥27 kg/m2 to <30 kg/m^2 (overweight) in the presence of at least one weight-related comorbidity.	Not routinely available as not recommended for use in NHS Scotland, SMC 2988 https://scottishmedicines.org.uk/media/10695/semaglutide-oral-tablets-wegovy-non-sub-final-sept-2026-for-website.pdf	20/10/2026
standardised allergen extract of pollen from white birch (Betula verrucosa) 12 SQ-Bet sublingual lyophilisate (Itulazax®)	2904	In adults and children (5 years or older) for the treatment of moderate-to-severe allergic rhinitis and/or conjunctivitis induced by pollen from the birch homologous. It is indicated in patients with a clinical history of symptoms despite use of symptom-relieving medication and a positive test of sensitisation to a member of the birch homologous group (skin prick test and/or specific IgE). **SMC restriction:** for use in adults, 18 to 65 years.	Not routinely available as the ADTC is waiting for further advice from local clinical experts	20/10/2026
tocilizumab 162mg solution for injection in pre-filled syringe, pre-filled pen (Avtozma®)		For the reatment of giant cell arteritis (GCA) in adults.	Routinely available in line with local guidance	20/10/2026
upadacitinib 15mg prolonged-release tablets (Rinvoq®)	2879	For the treatment of giant cell arteritis in adults where tocilizumab is unsuitable, not tolerated or has failed.	Routinely available in line with national guidance, SMC 2879 https://scottishmedicines.org.uk/media/10606/upadacitinib-rinvoq-final-july-2026-for-website.pdf	20/10/2026

Name	Unique identifier	Condition being treated	NHS Grampian decision	Date of decision
Voltarol® Ophtha Multidose 0.1% eye drops (diclofenac sodium)		- Inhibition of peroperative miosis during cataract surgery (Voltarol Ophtha Multidose has no intrinsic mydriatic properties and does not replace standard mydriatic agents). - Treatment of post-operative inflammation in cataract surgery. - Control of ocular pain and discomfort associated with corneal epithelial defects after excimer PRK surgery or accidental non-penetrating trauma. - Control of inflammation after Argon Laser Trabeculoplasty (ALT). - The relief of the ocular signs and symptoms of Seasonal Allergic Conjunctivitis (SAC). - Treatment of inflammation and discomfort after strabismus surgery - Treatment of ocular pain and discomfort after radial keratotomy	This medicine is now withdrawn from use/discontinued	20/10/2026
Voltarol® Ophtha Unit Dose 0.1% preservative-free eye drops (diclofenac sodium)		- Inhibition of peroperative miosis during cataract surgery (Voltarol Ophtha has no intrinsic mydriatic properties and does not replace standard mydriatic agents). - Treatment of post-operative inflammation in cataract surgery. - Control of ocular pain and discomfort associated with corneal epithelial defects after excimer PRK surgery or accidental non-penetrating trauma. - Control of inflammation after Argon Laser Trabeculoplasty (ALT). - The relief of the ocular signs and symptoms of Seasonal Allergic Conjunctivitis (SAC). - Treatment of inflammation and discomfort after strabismus surgery - Treatment of ocular pain and discomfort after radial keratotomy	This medicine is now withdrawn from use/discontinued	20/10/2026

Name	Unique identifier	Condition being treated	NHS Grampian decision	Date of decision
vutrisiran 25mg solution for injection in prefilled syringe (Amvuttra®)	2900	For the treatment of wild-type or hereditary transthyretin amyloidosis in adult patients with cardiomyopathy (ATTR-CM). **SMC restriction:** as monotherapy for the treatment of adult patients with wild-type or hereditary ATTR-CM.	Not routinely available as the ADTC is waiting for further advice from local clinical experts	20/10/2026
Zepatier® 50mg/100mg tablets (elbasvir/grazoprevir)		Treatment of chronic hepatitis C (CHC) in adults. (The efficacy of elbasvir-grazoprevir has not been demonstrated in genotypes 2, 3, 5 and 6. Elbasvir-grazoprevir is not recommended in patients infected with these genotypes).	This medicine is now withdrawn from use/discontinued	20/10/2026